HER2-LOW EXPRESSING BREAST CANCER

Clinical trials for HER2-LOW EXPRESSING BREAST CANCER explained in plain language.

Never miss a new study

Get alerted when new HER2-LOW EXPRESSING BREAST CANCER trials appear

Sign up with your email to follow new studies for HER2-LOW EXPRESSING BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet recruiting 1 Completed 1

Tracking a new hope for Tough-to-Treat breast cancer

Disease control Recruiting now

This study aims to understand how well a targeted drug called trastuzumab deruxtecan works for people with advanced, hard-to-treat breast cancer that has a specific marker (HER2-low). It will follow over 1,100 patients in Europe who are already receiving this drug or standard che…

Matched conditions: HER2-LOW EXPRESSING BREAST CANCER

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control

Last updated Mar 30, 2026 14:34 UTC

HER2-LOW EXPRESSING BREAST CANCER

Get alerted when new HER2-LOW EXPRESSING BREAST CANCER trials appear

Tracking a new hope for Tough-to-Treat breast cancer